Composition with aging-delaying and Anti-inflammatory effects, preparation method therefor, and use thereof

Abstract

A composition that exerts aging-delaying and anti-inflammatory effects by improving energy metabolism and mitochondrial function, a preparation method therefor, and use thereof. The composition comprises the following starting materials in parts by weight: 1-100 parts by weight of ergothioneine, 1-100 parts by weight of pyrroloquinoline quinone (PQQ) or a derivative thereof, and 20-1000 parts by weight of component C. The component C is β-nicotinamide mononucleotide (NMN), or nicotinamide riboside (NR) or a derivative thereof. Research has found that the combination of ergothioneine, PQQ or the derivative thereof, and NR or the derivative thereof or NMN can achieve a synergistic effect, with the anti-aging and anti-inflammatory effects being more significant than those of ergothioneine, PQQ or the derivative thereof, NR or the derivative thereof, or NMN alone.

Description

A composition with anti-aging and anti-inflammatory effects, its preparation method, and its uses.

[0001] Cross-reference to related applications

[0002] This application claims priority to Chinese Patent Application No. 202411179547.2, filed on August 26, 2024, entitled "A composition with anti-aging and anti-inflammatory effects and a method for its preparation and its use", the entire contents of which are incorporated herein by reference. Technical Field

[0003] This application relates to the field of pharmaceutical technology, specifically to a composition and preparation method with anti-aging and anti-inflammatory effects, and its uses. Background Technology

[0004] Aging refers to the progressive decline in an organism's physiological and psychological adaptability to the environment, gradually leading to death. Aging can be divided into two categories: physiological aging and pathological aging. The former refers to the physiological degeneration process that occurs after maturity, while the latter is the age-related changes caused by various external factors (including various diseases). In practice, the two are difficult to distinguish. In short, aging is the inevitable result of the combined effects of many pathological, physiological, and psychological processes; it is a biological and psychological process in the final stage of individual growth and development.

[0005] Nicotinamide adenine dinucleotide (NAD) + NAD+ is an important coenzyme in cellular redox processes, including serine biosynthesis, fatty acid oxidation, and glycolysis. + NADH and NAD can interconvert during redox processes, but the total amount remains unchanged. + It is an indispensable electron carrier in the cellular energy metabolism pathway, participating in mediating cellular energy metabolism, DNA repair, and stress response.

[0006] NAD in normal cells + A deficiency can cause a range of age-related diseases, such as neurological disorders, atherosclerosis, vision loss, diabetes, osteoarthritis, weakened immunity, and disorders of kidney and lipid metabolism. + Upregulation is beneficial for neuroprotection and trauma repair. Increasing NAD+ + Levels of NAD can enhance the proliferation and regeneration of neural stem cells and prevent Alzheimer's disease and amyotrophic lateral sclerosis (ALS). + Upregulation can prevent acute liver and kidney injury, hepatic lipid accumulation, improve kidney function and liver regeneration capacity, and reduce liver fibrosis. Furthermore, when NAD+ levels in the body... +When levels are elevated, extracellular matrix deposition in the kidneys can be reduced, alleviating inflammation.

[0007] NAD + Declining levels are associated with various aging-related processes. Aging is linked to abnormal activation, or "inflammation," of pro-inflammatory immune cells, leading to persistent low-grade inflammation. This is partly due to the increasing proportion of senescent cells in tissues, which continuously secrete associated phenotypes (SASPs). The accumulation of these phenotypes promotes a pro-inflammatory state in macrophages, thus generating inflammation. Studies have shown that, under SASP stimulation, macrophage NAD+ levels... + The expression of consuming enzymes, including CD38 and PARP, will increase significantly, directly causing NAD+ degradation. + Levels decline. NAD+ levels decrease during human aging. + The decline in [certain substances] is considered a major cause of diseases and disabilities, such as hearing and vision loss, cognitive and motor dysfunction, immune deficiencies, arthritis caused by autoimmune inflammatory responses, metabolic disorders, and cardiovascular diseases.

[0008] Summary of the Invention

[0009] Therefore, the technical problem to be solved by this application is to provide a composition with anti-aging and anti-inflammatory effects, a preparation method thereof, and its use.

[0010] Therefore, this application provides the following technical solution:

[0011] A composition having anti-aging and anti-inflammatory effects comprises the following raw materials in parts by weight: 1-100 parts by weight of ergothioneine, 1-100 parts by weight of PQQ or its derivatives, and 20-1000 parts by weight of component C.

[0012] The component C is NMN, or NR or its derivatives.

[0013] Optionally, the derivatives of PQQ include salts or crystals of PQQ; further, the salts of PQQ are disodium pyrroloquinoline quinone (PQQ-2Na) or trisodium pyrroloquinoline quinone.

[0014] Optionally, the derivatives of NR include salts, crystals, or chlorides of NR.

[0015] Optional ingredients include the following parts by weight:

[0016] Ergothioneine 25 parts by weight, PQQ 20 parts by weight, and NRCl 300 parts by weight;

[0017] Alternatively, 25 parts by weight of ergothioneine, 20 parts by weight of PQQ, and 300 parts by weight of NMN;

[0018] Alternatively, 100 parts by weight of ergothioneine, 1 part by weight of PQQ, and 1000 parts by weight of NRCl;

[0019] Alternatively, 1 part by weight of ergothioneine, 1 part by weight of PQQ, and 1000 parts by weight of NRCl;

[0020] Alternatively, 100 parts by weight of ergothioneine, 100 parts by weight of PQQ, and 20 parts by weight of NRCl;

[0021] Alternatively, 1 part by weight of ergothioneine, 100 parts by weight of PQQ, and 20 parts by weight of NRCl;

[0022] Alternatively, 100 parts by weight of ergothioneine, 1 part by weight of PQQ, and 20 parts by weight of βNMN;

[0023] Alternatively, 1 part by weight of ergothioneine, 100 parts by weight of PQQ, and 1000 parts by weight of NMN.

[0024] A method for preparing the composition having anti-aging and anti-inflammatory effects includes selecting raw materials according to the formula and then mixing them.

[0025] Optionally, it may also include adding excipients and / or carriers to form an acceptable dosage form.

[0026] Optionally, the temperature is controlled below 25°C and the humidity is controlled below 50%. Then, raw materials are selected according to the formula, mixed, and excipients and / or carriers are added or not added to prepare an acceptable dosage form.

[0027] A formulation comprising the composition having anti-aging and anti-inflammatory effects, and excipients and / or a formulation-permitted carrier.

[0028] Optionally, the formulation form includes liquid formulations and solid formulations.

[0029] Optionally, the formulation may be in the form of powder, powder for injection, injection, tablet, capsule, granule or ointment.

[0030] Optionally, the tablets include sugar-coated tablets, film-coated tablets, enteric-coated tablets, orally disintegrating tablets, and lozenges;

[0031] Alternatively, the capsule may include hard capsules.

[0032] The use of the composition or preparation having anti-aging and anti-inflammatory effects in the preparation of products with anti-aging and anti-inflammatory effects.

[0033] Optionally, the product may include pharmaceuticals or food.

[0034] A method for delaying aging and reducing inflammation includes administering the composition or the formulation to a patient in need.

[0035] The technical solution of this application has the following advantages:

[0036] 1. This application provides a composition with anti-aging and anti-inflammatory effects, comprising the following raw materials in parts by weight: 1-100 parts by weight of ergothioneine, 1-100 parts by weight of PQQ or its derivatives, and 20-1000 parts by weight of component C; wherein component C is NMN, or NR or its derivatives; this application has found that the combination of ergothioneine, PQQ or its derivatives, and NMN, or NR or its derivatives can have a synergistic effect, and the anti-aging and anti-inflammatory effects are more significant than those of ergothioneine, PQQ or its derivatives, NMN, NR or their derivatives alone.

[0037] 2. This application provides a composition with anti-aging and anti-inflammatory effects, comprising the following raw materials in parts by weight: 25 parts by weight of ergothioneine, 20 parts by weight of PQQ, and 300 parts by weight of NMN or NRCl and its derivatives; the research of this application found that, under the above ratio, the combination of ergothioneine, PQQ, and NRCl can achieve a more significant synergistic effect, and the anti-aging and anti-inflammatory effects are more significant than those under other ratios. Attached Figure Description

[0038] To more clearly illustrate the technical solutions in the specific embodiments of this application or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0039] Figure 1 shows the mitochondrial fluorescence intensity results for each group in the experimental examples of this application. Detailed Implementation

[0040] The following embodiments are provided to better understand this application and are not limited to the preferred embodiments described herein. They do not constitute a limitation on the content and scope of protection of this application. Any product that is the same as or similar to this application, derived by anyone under the guidance of this application or by combining features of this application with other prior art, falls within the scope of protection of this application.

[0041] For experiments not specifically described in the examples, the procedures or conditions should be followed according to the conventional experimental procedures described in the literature in this field. Reagents or instruments whose manufacturers are not specified are all commercially available conventional reagent products.

[0042] The ergothionein used in this application was purchased from Shanghai Ergothionein Biotechnology Group Co., Ltd., and its purity is ≥99%.

[0043] The disodium pyrroloquinoline quinone (PQQ source) was purchased from Fujian Kanghong Biotechnology Co., Ltd., with a purity of ≥99%.

[0044] Nicotinamide ribochloride (NRCl), purchased from ChromaDex Group, purity ≥95%;

[0045] β-Nicotinamide mononucleotide (NMN) was purchased from Uthever by Effepharm. TM NMN products with a purity of ≥99%.

[0046] Example

[0047] This embodiment provides a composition with anti-aging and anti-inflammatory effects, the formulation of which is shown in the table below. Note: The raw material source of PQQ in the formulation below is disodium pyrroloquinoline quinone. The PQQ content in the table is the content of pyrroloquinoline quinone after conversion from disodium pyrroloquinoline quinone. The conversion formula is: PQQ content = mass of disodium pyrroloquinoline quinone / relative molecular weight of disodium pyrroloquinoline quinone × relative molecular weight of PQQ.

[0048] Table 1. Formula

[0049] The preparation method of the compositions with anti-aging and anti-inflammatory effects in Examples 1-8 above includes the following steps: weighing the raw materials according to the formula and mixing them evenly.

[0050] Example 9: Capsules

[0051] This embodiment provides a method for preparing the compositions of Examples 1-8 into capsules, comprising the following steps:

[0052] The production process employs conventional mixing and hard capsule filling techniques. The entire process requires strict temperature and humidity control, with the temperature maintained below 25°C and humidity below 50%. Taking the composition in Example 1 as an example, the raw materials are weighed according to the formula, mixed evenly, and then capsules are prepared using conventional processes at 25°C and 50% relative humidity. After being stored at 30°C and 75% relative humidity for 6 months, the loss rate of the active ingredient mixture in the capsules is only 2.42%, effectively reducing the loss and degradation of active ingredients during production and ensuring that the finished product meets efficacy requirements. Active ingredient loss rate = (Active ingredient content before 6 months - Active ingredient content after 6 months) / Active ingredient content before 6 months × 100%.

[0053] Comparative Example

[0054] This embodiment provides a method for preparing the compositions of Examples 1-8 into capsules, comprising the following steps:

[0055] Taking the composition in Example 1 as the active ingredient, raw materials were weighed according to the formula, mixed evenly, and then capsule preparations were prepared according to the conventional process under the conditions of a temperature of 30 °C and a relative humidity of 75%. After being placed for 6 months under the conditions of a temperature of 30 °C and a relative humidity of 75%, the loss rate of the active ingredient in the raw material mixture in the capsules was more than 30%.

[0056] Experimental Example This experimental example examines the anti-aging and anti-inflammatory effects of the composition of the present application

[0057] 1. Detection Materials

[0058] 1.1. Sample Preparation Information

[0059] The sample solvents were all standard dilution water.

[0060] Positive control: Dexamethasone, white powder, batch number C2110208, Shanghai Aladdin Biochemical Technology Co., Ltd., the solvent is DMSO. L-Reduced glutathione (hereinafter referred to as glutathione), white powder, batch number SLCG8572, Sigma, the solvent is standard dilution water.

[0061] Experimental samples: The compositions of Examples 1-8, prepared as needed; separate ergothioneine, PQQ, NRCl, NMN. The experimental samples were diluted to the required concentration with standard dilution water and prepared as needed.

[0062] 1.2. Experimental Animals

[0063] Zebrafish were all raised in fish-raising water at 28 °C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, the conductivity was 450-550 μS / cm; the pH was 6.5-8.5; the hardness was 50-100 mg / L CaCO3). The license number for the use of experimental animals was: SYXK(Zhe)2022-0004. The feeding management met the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethical review number was: IACUC-2024-7045-5-01.

[0064] 1.3. Instruments, Consumables and Reagents

[0065] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); Precision electronic balance (CP214, OHAUS, USA); Motorized focusing continuous zoom fluorescence microscope (AZ100, Nikon, Japan); Zeiss fluorescence microscope (AXIO Zoom.V16, ZEISS, Germany); Multifunctional microplate reader (SPARK, TECAN, Austria); Fully automated nucleic acid extractor (Auto-Pure32A, Hangzhou Aosheng Instrument Co., Ltd., China); Conventional PCR amplification instrument (T100, BIO-RAD, Singapore); Real-time PCR instrument (CFX Connect, BIO-RAD, Singapore); Ultraviolet-Vis spectrophotometer (Nanodrop2000, Thermo, USA); Microplate mini centrifuge (BE-6100, Haimen Qilinbei Instrument Manufacturing Co., Ltd., China).

[0066] Cobalt chloride hexahydrate (batch number D1916093, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Methylcellulose (batch number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Rhodamine 123 (batch number R2304141, Yisheng Biotechnology (Shanghai) Co., Ltd., China); Tissue Mitochondrial Isolation Kit (batch number 010524240403, Shanghai Beyotime Biotechnology Co., Ltd., China); Dimethyl sulfoxide (DMSO, batch number I2229063, Shanghai Aladdin Biochemical Technology Co., Ltd., China); ChamQ UniversalSYBR qPCR (catalog number Q711-03, Novizan Biosciences Co., Ltd., China); FHifair III 1st Strand cDNA Synthesis SuperMix for qPCR (batch number H6326010, Yisheng Biotechnology (Shanghai) Co., Ltd., China); Pre-loaded magnetic bead universal RNA extraction kit C (catalog number TL643-03C, ONREW, China); Sodium dodecyl sulfate (batch number L212807, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Coenzyme INAD(H) content assay kit (batch number 2310002, Solarbio, China); BCA protein concentration assay kit (batch number 17K04A89, Wuhan Boster Biological Engineering Co., Ltd., China).

[0067] 2. Detection Method

[0068] 2.1. Anti-inflammatory effects

[0069] Sodium dodecyl sulfate (SLS) may trigger a stimulating response in the body. When this stimulant enters the zebrafish, it induces an inflammatory response, causing neutrophils to initiate an immune response, migrate to the skin epidermis, and aggregate. IL-17A and its secretory cells, CD4+ Th17 cells, participate in the body's clearance of pathogens such as bacteria, fungi, mycoplasma, and chlamydia, and can cause neutrophils and / or monocytes to aggregate at sites of inflammation. IL-6 can promote the upregulation of neutrophil function and promote and regulate the secretion of inflammatory mediators such as cytokines, adhesion molecules, and nitric oxide. TNF-α is the earliest and most important inflammatory cytokine to appear during the inflammatory response and can activate neutrophils.

[0070] Wild-type AB strain zebrafish at 2 days post-fertilization (2 dpf) were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well (experimental group). Samples were administered in water (final concentrations shown in Tables 2-4), with a positive control of dexamethasone at 3.92 μg / mL, in 3 mL volumes per well. Except for the normal control group, all other experimental groups were administered sodium dodecyl sulfate (60 μg / mL, 3 mL per well) in water to establish a zebrafish skin inflammation model. Three parallel experiments were set up. After treatment at 28℃ for 24 h, total RNA was extracted from each group of zebrafish using a pre-loaded magnetic bead universal RNA extraction kit C. The concentration and purity of total RNA were determined using a UV-Vis spectrophotometer. 2.00 μg of total RNA from zebrafish samples was used to synthesize 20.0 μL of cDNA according to the instructions of the cDNA first-strand synthesis kit. The expression of β-actin, il-17a, tnf-α, and il-6 genes was detected by q-PCR. Using β-actin as an internal control for gene expression, the relative RNA expression levels of il-17a, tnf-α, and il-6 genes were calculated. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software, and p < 0.05 was considered statistically significant.

[0071] 2.2. Effects on improving energy metabolism

[0072] Wild-type AB strain zebrafish at 6 hpf (6 hours post-fertilization) were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well. The samples were administered via water solution (final concentrations shown in Table 5), and a normal control group was also included. Each well contained 3 mL of solution. Six experiments were performed in parallel. After treatment at 28℃ for 6 days, zebrafish samples were collected according to the instructions of the coenzyme INAD(H) content assay kit, and the NAD content of the zebrafish was measured using a multi-functional microplate reader. + The NADH content was detected and analyzed in zebrafish from each experimental group. +The NADH ratio was used to evaluate the impact of the sample on energy metabolism rate through statistical analysis. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software; p < 0.05 was considered statistically significant.

[0073] 2.3. Evaluation of enhanced mitochondrial function (mitochondrial fluorescence intensity)

[0074] Transgenic green fluorescent zebrafish with mitochondrial fluorescence (4 dpf, 4 days post-fertilization) were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well. The sample was administered in water (final concentration shown in Table 6), with a positive control of glutathione at a concentration of 500 μg / mL. A normal control group and a model control group were also included, with a volume of 3 mL per well. After treatment at 28℃ for 1 day, except for the normal control group, all other experimental groups were administered cobalt chloride (1 mg / mL, 3 mL per well) in water to establish a zebrafish mitochondrial damage model. After further treatment at 28℃ for 3 hours, 10 zebrafish from each experimental group were randomly selected and photographed under a fluorescence microscope. Data were collected using NIS-Elements D 3.20 advanced image processing software, and the mitochondrial fluorescence intensity of the zebrafish was analyzed. The statistical analysis results of this index were used to evaluate the mitochondrial enhancement efficacy of the samples. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software; p < 0.05 indicated statistical significance.

[0075] 2.4. Evaluation of enhanced mitochondrial function (mitochondrial membrane potential)

[0076] Zebrafish (albino) with a 4dpf melanin allele mutation were randomly selected and placed in 6-well plates, with 30 zebrafish treated in each well. The samples were administered in water (final concentrations shown in Table 7), with a positive control of glutathione at a concentration of 500 μg / mL. A normal control group and a model control group were also included, with a volume of 3 mL per well. The treatment was repeated in duplicate. After treatment at 28℃ for 1 day, except for the normal control group, all other experimental groups were administered cobalt chloride (concentration 1 mg / mL, 3 mL per well) in water to establish a zebrafish mitochondrial damage model. After further treatment at 28℃ for 3 hours, the samples were collected. The zebrafish from each experimental group were stained using a tissue mitochondrial isolation kit and Rhodamine 123. After staining, each experimental group was photographed under a Zeiss fluorescence microscope. Data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The fluorescence intensity of the zebrafish mitochondrial membrane potential was analyzed, and the statistical analysis results of this index were used to evaluate the mitochondrial enhancement efficacy of the samples. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software, and p < 0.05 indicated that the difference was statistically significant.

[0077] 3. Test Results

[0078] Table 2. Relative expression levels of il-17a *, **, and *** represent differences compared to the model control group, respectively, indicating p < 0.05, p < 0.01, and p < 0.001. a, b, c, and d indicate statistical differences among themselves, p < 0.05.

[0079] IL-17A, a pro-inflammatory cytokine secreted by skin immune cells, promotes inflammation and accelerates skin aging. Therefore, the expression level of the IL-17A gene reflects the state of skin inflammation. High IL-17A gene expression indicates a high content of skin inflammatory factors, meaning the composition has a poor anti-inflammatory effect, while low IL-17A gene expression indicates a low content of skin inflammatory factors, meaning the composition has a good anti-inflammatory effect. The results show that the relative expression level of the IL-17A gene in the model control group was significantly higher than that in the normal control group, indicating that the model control group was successfully constructed. Compared with the model control group, the relative expression level of the IL-17A gene in the positive control, the example group, and the individual raw materials was significantly lower than that in the model control group, indicating that the positive control, the example, and the individual raw materials all have significant anti-inflammatory effects on the skin. The relative expression level of the IL-17A gene in the example group was significantly lower than that of the individual raw materials, indicating that the components in the example group formulation have a significant synergistic effect and can significantly combat skin inflammation, especially the formulation of Example 1, which is the best.

[0080] Table 3. Relative expression levels of il-6 *, **, and *** represent differences compared to the model control group, respectively, indicating p < 0.05, p < 0.01, and p < 0.001. a and b indicate statistical differences between them, p < 0.05.

[0081] Since the pro-inflammatory cytokine IL-6 can promote the upregulation of neutrophil function and promote and regulate the secretion of inflammatory mediators such as cytokines, adhesion molecules, and nitric oxide, the expression level of the IL-6 gene reflects the state of inflammation. High IL-6 gene expression reflects a high level of inflammatory factors in the body, indicating a poor anti-inflammatory effect of the composition, while low IL-6 gene expression reflects a low level of inflammatory factors in the body, indicating a superior anti-inflammatory effect of the composition. The results in the table above show that compared with the normal control group, the model control group showed a significant increase, and the difference between the two was statistically significant, indicating that the model control group was successfully constructed. Compared with the model control group, the positive control, the example group, and the individual raw materials all significantly reduced the relative expression level of the IL-6 gene, indicating that the positive control, the example group, and the individual raw materials have a significant effect in reducing the expression level of the pro-inflammatory cytokine IL-6. This indicates that the positive control, the example, and the individual raw materials all have significant anti-inflammatory effects. The relative expression level of the IL-6 gene in the example group was significantly lower than that of the individual raw materials, indicating that there is a significant synergistic effect among the components in the example group formulation, which can achieve a significant anti-inflammatory effect, especially the formulations of Examples 1 and 2.

[0082] Table 4. Relative expression levels of tnf-α *, **, and *** represent differences compared to the model control group, respectively, indicating p < 0.05, p < 0.01, and p < 0.001. a, b, and c indicate statistical differences among them, p < 0.05.

[0083] Since the pro-inflammatory cytokine TNF-α is the earliest and most important inflammatory cytokine to appear during the inflammatory response, and can activate neutrophils, the expression level of the TNF-α gene reflects the state of inflammation in the body. High TNF-α gene expression reflects a high content of inflammatory factors in the body, indicating a poor anti-inflammatory effect of the composition, while low TNF-α gene expression reflects a low content of inflammatory factors in the body, indicating a superior anti-inflammatory effect of the composition. The results in the table above show that compared with the normal control group, the model control group showed a significant increase, and the difference between the two was statistically significant, indicating that the model control group was successfully constructed. Compared with the model control group, the positive control, the example group, and the individual raw materials all reduced the relative expression level of the TNF-α gene, indicating that the positive control, the example group, and the individual raw materials have significant anti-inflammatory effects in the body. The relative expression level of the TNF-α gene in the example group was significantly lower than that of the individual raw materials, indicating that the components in the formulation of the example group have a significant synergistic effect and can achieve a significant anti-inflammatory effect, especially Example 1.

[0084] Table 5, NAD + / NADH content ratio *, **, and *** represent the values ​​compared to the model control group, respectively, indicating p < 0.05, p < 0.01, and p < 0.001.

[0085] The results in the table above indicate that, compared with the normal control group, the composition of this application, which has anti-aging and anti-inflammatory effects, increases NAD5 levels. + The effect of the NADH content ratio indicates that the composition has the effect of significantly improving the energy metabolism rate, which can alleviate the problem of poor energy metabolism after aging, especially Examples 1 and 2 are the best.

[0086] Table 6. Mitochondrial fluorescence intensity *, **, and *** represent the values ​​compared to the model control group, respectively, indicating p < 0.05, p < 0.01, and p < 0.001.

[0087] The results in the table above and Figure 1 (partial zebrafish examples) show that, compared with the normal control group, the model control group showed a significant decrease, with a statistically significant difference, indicating that the model was successfully constructed. Compared with the model control group, the composition of the example group and the positive control group significantly increased mitochondrial fluorescence intensity, while the individual raw materials did not significantly increase mitochondrial fluorescence intensity. This demonstrates that the composition of the example group increases the number of mitochondria and enhances mitochondrial function through the synergistic effect of each component, which can alleviate the problem of decreased mitochondrial number and impaired mitochondrial function after aging.

[0088] Table 7. Mitochondrial membrane potential *, **, and *** represent differences compared to the model control group, respectively, indicating p < 0.05, p < 0.01, and p < 0.001. a, b, c, and d indicate statistical differences among themselves, p < 0.05.

[0089] The results in the table above show that, compared with the normal control group, the model control group showed a significant decrease, with a statistically significant difference, indicating that the model control group was successfully constructed. Compared with the model control group, the example group, the positive control group, and the single ingredient significantly increased mitochondrial membrane potential, while the mitochondrial membrane potential of the example group was significantly better than that of the single ingredient group. This indicates that the composition of the example group improves mitochondrial status and enhances mitochondrial function through the synergistic effect of the components, which can alleviate the problem of decreased mitochondrial quantity and function after aging, especially Example 1, which is the best.

[0090] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.

Claims

1. A composition having anti-aging and anti-inflammatory effects, characterized in that, The raw materials include the following parts by weight: 1-100 parts by weight of ergothioneine, 1-100 parts by weight of PQQ or its derivatives, and 20-1000 parts by weight of component C; The component C is NMN, or NR or its derivatives.

2. The composition with anti-aging and anti-inflammatory effects according to claim 1, characterized in that, The ingredients include the following parts by weight: Ergothioneine 25 parts by weight, PQQ 20 parts by weight, and NRCl 300 parts by weight; Alternatively, 25 parts by weight of ergothioneine, 20 parts by weight of PQQ, and 300 parts by weight of NMN; Alternatively, 100 parts by weight of ergothioneine, 1 part by weight of PQQ, and 1000 parts by weight of NRCl; Alternatively, 1 part by weight of ergothioneine, 1 part by weight of PQQ, and 1000 parts by weight of NRCl; Alternatively, 100 parts by weight of ergothioneine, 100 parts by weight of PQQ, and 20 parts by weight of NRCl; Alternatively, 1 part by weight of ergothioneine, 100 parts by weight of PQQ, and 20 parts by weight of NRCl; Alternatively, 100 parts by weight of ergothioneine, 1 part by weight of PQQ, and 20 parts by weight of NMN; Alternatively, 1 part by weight of ergothioneine, 100 parts by weight of PQQ, and 1000 parts by weight of NMN.

3. A method for preparing a composition having anti-aging and anti-inflammatory effects as described in any one of claims 1-2, characterized in that, This includes selecting raw materials according to the formula and then mixing them.

4. The method for preparing the composition with anti-aging and anti-inflammatory effects according to claim 3, characterized in that, This also includes adding excipients and / or carriers to formulate an acceptable dosage form; Optionally, the temperature is controlled below 25°C and the humidity is controlled below 50%. Then, raw materials are selected according to the formula, mixed, and excipients and / or carriers are added or not added to prepare an acceptable dosage form.

5. A formulation, characterized in that, The composition contains the anti-aging and anti-inflammatory effects as described in any one of claims 1-2, and excipients and / or a carrier permitted by the formulation.

6. The formulation according to claim 5, characterized in that, The formulation forms include liquid formulations and solid formulations.

7. The formulation according to claim 6, characterized in that, The formulation may be in the form of powder, powder for injection, injection, tablet, capsule, granule or ointment.

8. The formulation according to claim 7, characterized in that, The tablets include sugar-coated tablets, film-coated tablets, enteric-coated tablets, orally disintegrating tablets, or lozenges; Alternatively, the capsule may include hard capsules.

9. Use of the composition having anti-aging and anti-inflammatory effects as described in any one of claims 1-2 or the formulation as described in any one of claims 5-8 in the preparation of products with anti-aging and anti-inflammatory effects.

10. The use according to claim 9, characterized in that, The products include pharmaceuticals or food.

11. A method for delaying aging and reducing inflammation, comprising administering to a patient in need the composition of any one of claims 1-2 or the formulation of any one of claims 5-8.

Images